| Assay ID | Title | Year | Journal | Article |
|---|
| AID1870889 | Agonist activity at LPA2 receptor (unknown origin) expressed in cells assessed as calcium mobilization at 10 uM by Fluo-4 NW dye based assay | 2022 | Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
| Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA |
| AID239112 | Binding affinity for Lysophosphatidic acid receptor 3 expressed in RH7777 rat hepatoma cells | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
| Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. |
| AID702438 | Antagonist activity at human LPA1 receptor expressed in HEK293 cells assessed as inhibition of LPA-induced AP-TGF-alpha release treated 5 mins before LPA addition measured after 60 mins | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
| Synthesis and biological evaluation of optically active Ki16425. |
| AID1870886 | Antagonist activity at LPA3 receptor (unknown origin) expressed in cells assessed as blockade of LPA-induced calcium mobilization measured after 120 secs by Fluo-4 NW dye based assay | 2022 | Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
| Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA |
| AID457516 | Agonist activity at LPA1 expressed in human chem1 cells assessed as intracellular calcium mobilization by FLIPR assay | 2010 | Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
| Synthesis, in vitro structure-activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents. |
| AID246334 | Inhibition of LPA-induced calcium transients in PC-3 cells; Not applicable | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
| Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. |
| AID1870887 | Antagonist activity at LPA3 receptor (unknown origin) expressed in cells assessed as maximal blockade of LPA-induced calcium mobilization at 10 uM measured after 120 secs by Fluo-4 NW dye based assay relative to control | 2022 | Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
| Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA |
| AID307611 | Antagonist activity at human recombinant LPA1 receptor expressed in CHOK1 cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx | 2007 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
| Synthesis and evaluation of isoxazole derivatives as lysophosphatidic acid (LPA) antagonists. |
| AID248443 | Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA3 receptor | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
| Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. |
| AID673242 | Antagonist activity at LPA5 receptor in human isolated platelets assessed as inhibition of hexadecyl-LPA-induced platelet aggregation after 3 mins | 2012 | Bioorganic & medicinal chemistry letters, Aug-15, Volume: 22, Issue:16
| Selective non-lipid modulator of LPA5 activity in human platelets. |
| AID247751 | Inhibition of LPA-induced calcium transients in PC-3 cells | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
| Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. |
| AID246418 | Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor; No effect | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
| Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. |
| AID238591 | Binding affinity for Lysophosphatidic acid receptor in PC-3 cells | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
| Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. |
| AID706173 | Antagonist activity at LPA1 in human lung fibroblasts assessed as inhibition of LPA-induced contraction after 18 hrs by 3D collagen gel contraction assay | 2012 | Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
| Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts. |
| AID239111 | Binding affinity for Lysophosphatidic acid receptor 1 expressed in RH7777 rat hepatoma cells | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
| Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. |
| AID246420 | Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA3 receptor; No effect | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
| Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. |
| AID1870882 | Antagonist activity at LPA1 receptor (unknown origin) expressed in cells assessed as maximal blockade of LPA-induced calcium mobilization at 10 uM measured after 120 secs by Fluo-4 NW dye based assay relative to control | 2022 | Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
| Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA |
| AID239090 | Binding affinity for Lysophosphatidic acid receptor 2 expressed in RH7777 rat hepatoma cells | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
| Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. |
| AID1118227 | Competitive antagonist activity at human LPA1 receptor overexpressed in CHO cells assessed as inhibition of LPA-induced [35S]GTPgammaS binding by liquid scintillation counting | 2011 | MedChemComm, Mar-03, Volume: 2, Issue:4
| Development of a phosphatase-resistant, L-tyrosine derived LPA1/LPA3 dual antagonist. |
| AID457518 | Agonist activity at LPA5 expressed in human chem1 cells assessed as intracellular calcium mobilization by FLIPR assay | 2010 | Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
| Synthesis, in vitro structure-activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents. |
| AID1118228 | Competitive antagonist activity at N-terminal 3XHA-tagged human LPA3 receptor overexpressed in CHO cells assessed as inhibition of LPA-induced [35S]GTPgammaS binding by liquid scintillation counting | 2011 | MedChemComm, Mar-03, Volume: 2, Issue:4
| Development of a phosphatase-resistant, L-tyrosine derived LPA1/LPA3 dual antagonist. |
| AID1870881 | Antagonist activity at LPA1 receptor (unknown origin) expressed in cells assessed as blockade of LPA-induced calcium mobilization measured after 120 secs by Fluo-4 NW dye based assay | 2022 | Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
| Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA |
| AID248441 | Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA1 receptor | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
| Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. |
| AID307612 | Antagonist activity at LPA1 receptor in rat hepatic stellate cells assessed as inhibition of lysophosphatidic acid-induced intracellular calcium influx | 2007 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
| Synthesis and evaluation of isoxazole derivatives as lysophosphatidic acid (LPA) antagonists. |
| AID1870885 | Antagonist activity at LPA2 receptor (unknown origin) expressed in cells assessed as maximal blockade of LPA-induced calcium mobilization at 10 uM measured after 120 secs by Fluo-4 NW dye based assay relative to control | 2022 | Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
| Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA |
| AID702439 | Antagonist activity at LPA receptor in human PC3 cells assessed as inhibition of LPA-induced cell migration | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
| Synthesis and biological evaluation of optically active Ki16425. |
| AID457517 | Agonist activity at LPA3 expressed in human chem1 cells assessed as intracellular calcium mobilization by FLIPR assay | 2010 | Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
| Synthesis, in vitro structure-activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents. |
| AID1870884 | Antagonist activity at LPA2 receptor (unknown origin) expressed in cells assessed as blockade of LPA-induced calcium mobilization measured after 120 secs by Fluo-4 NW dye based assay | 2022 | Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
| Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA |
| AID248650 | Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA2 receptor; No effect | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
| Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. |
| AID702437 | Antagonist activity at human LPA2 receptor expressed in HEK293 cells assessed as inhibition of LPA-induced AP-TGF-alpha release treated 5 mins before LPA addition measured after 60 mins | 2012 | Bioorganic & medicinal chemistry letters, Jul-01, Volume: 22, Issue:13
| Synthesis and biological evaluation of optically active Ki16425. |
| AID246419 | Inhibition of LPA-induced calcium transients in RH7777 rat hepatoma cells expressing LPA2 receptor; No effect | 2005 | Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
| Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin. |
| AID457519 | Antagonist activity at LPA1 expressed in human chem1 cells assessed as effect on intracellular calcium mobilization by FLIPR assay | 2010 | Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2
| Synthesis, in vitro structure-activity relationship, and in vivo studies of 2-arylthiazolidine-4-carboxylic acid amides as anticancer agents. |
| AID1870883 | Antagonist activity at LPA1 receptor (unknown origin) expressed in cells assessed as blockade of LPA-induced calcium mobilization at 10 uM measured after 120 secs by Fluo-4 NW dye based assay | 2022 | Journal of medicinal chemistry, 08-25, Volume: 65, Issue:16
| Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1346019 | Mouse LPA1 receptor (Lysophospholipid (LPA) receptors) | 2003 | Molecular pharmacology, Oct, Volume: 64, Issue:4
| Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. |
| AID1346181 | Human LPA3 receptor (Lysophospholipid (LPA) receptors) | 2003 | Molecular pharmacology, Oct, Volume: 64, Issue:4
| Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. |
| AID1345175 | Human GPR87 (Class A Orphans) | 2007 | Biochemical and biophysical research communications, Nov-23, Volume: 363, Issue:3
| The orphan GPCR GPR87 was deorphanized and shown to be a lysophosphatidic acid receptor. |
| AID1346102 | Human LPA2 receptor (Lysophospholipid (LPA) receptors) | 2003 | Molecular pharmacology, Oct, Volume: 64, Issue:4
| Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |